Genetics in Parkinson’s disease, state-of-the-art and future perspectives
British Medical Bulletin · 13.03.2024 · 149 (1) · 60-71
DOI: 10.1093/bmb/ldad035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Medical Bulletin, online erschienen am 27.01.2024. Verfasst von L Trevisan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Largo P. Daneo 3, Genova, 161…. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is clinically characterized by the presence of motor (bradykinesia, rigidity, rest tremor and postural instability) and non-motor symptoms (cognitive impairment, autonomic dysfunction, sleep disorders, depression and hyposmia). The aetiology of PD is unknown except for a small but significant contribution of monogenic forms. Sources of data No new data were generated or analyzed in support of this review. Areas of agreement Up to 15% of PD patients carry pathogenic variants in PD-associated genes. Some of these genes are associated with mendelian inheritance, while others act as risk factors. Genetic background influences age of onset, disease course, prognosis and therapeutic response. Areas of controversy Genetic testing is not routinely offered in the clinical setting, but it may have relevant implications, especially in terms of prognosis, response to therapies and inclusion in clinical trials. Widely adopted clinical guidelines on genetic testing are still lacking and open to debate. Some new genetic associations are still awaiting confirmation, and selecting the appropriate genes to be included in diagnostic panels represents a difficult task. Finally, it is still under study whether (and to which degree) specific genetic forms may influence the outcome of PD therapies. Growing points Polygenic Risk Scores (PRS) may represent a useful tool to genetically stratify the population in terms of disease risk, prognosis and therapeutic outcomes. Areas timely for developing research The application of PRS and integrated multi-omics in PD promises to improve the personalized care of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Largo P. Daneo 3, Genova, 16132, Italy.
- IRCCS Ospedale Policlinico San Martino - SS Centro Tumori Ereditari, Largo R. Benzi 10, Genova, 16132, Italy.
- IRCCS Ospedale Policlinico San Martino- UOC Genetica Medica, Largo R. Benzi 10, Genova, 16132, Italy.
- Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza 35, Milan, 20122, Italy.
- Neurology Unit, Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico, Via Festa del Perdono 7, Milan, 20122, Italy.
- Department of Experimental Medicine, Section of Human Physiology, University of Genoa, Viale Benedetto XV/3, Genova, 16132, Italy.
ORCID-Profile: L Trevisan, A Gaudio
Förderung
- Italian Ministry of Health
Zitieren
APA
Trevisan, L., Gaudio, A., Monfrini, E., Avanzino, L., Di Fonzo, A., & Mandich, P. (2024). Genetics in Parkinson’s disease, state-of-the-art and future perspectives. British Medical Bulletin, 149(1), 60-71. https://doi.org/10.1093/bmb/ldad035
Vancouver
Trevisan L, Gaudio A, Monfrini E, Avanzino L, Di Fonzo A, Mandich P. Genetics in Parkinson’s disease, state-of-the-art and future perspectives. British Medical Bulletin. 2024;149(1):60-71. doi:10.1093/bmb/ldad035
BibTeX
@article{Trevisan2024,
author = {Trevisan, L and Gaudio, A and Monfrini, E and Avanzino, L and Di Fonzo, A and Mandich, P},
title = {Genetics in Parkinson’s disease, state-of-the-art and future perspectives},
journal = {British Medical Bulletin},
year = {2024},
volume = {149},
number = {1},
pages = {60--71},
doi = {10.1093/bmb/ldad035}
}
EUVIMED